EXHIBIT 14



Biacore measurements for the interaction between captured antibody (25 μg/ml) and soluble rhTNFα (2.5 - 1000 nM)

Sample	Ab Class	Captured antibody	Stoich. range	Individual Biacore Kinetic Rate Parameters		
				On-rate (M-1s-1)	Off-rate (s-1)	K_D (M)
1	Murine IgG	Peptech 001	0.23 - 0.47	1.04E+06	5.02E-04	4.83E-10
2	Murine IgG	Peptech 25	0.31 - 0.64	8.31E+05	1.85E-04	2.23E-10
3	Murine IgG	Peptech 37	- 0.03 - 0.09[c]	4.25E+05	1.47E-03	3.45E-09
4	Murine IgG	[ab]Peptech 42	- 0.01 - 0.46	3.73E+04	3.85E-04	1.03E-08
5	Murine IgG	[ab]Peptech 53	- 0.04 - 0.60	4.08E+04	4.08E-04	9.99E-09
6	Murine IgG	Peptech 54	0.27 - 0.52	6.61E+05	3.37E-04	5.10E-10
7	Human IgG1	Remicade	0.45 - 0.81	6.26E+05	3.56E-05	5.69E-11
8	Murine IgG3	Segard	0.55 - 0.91	6.44E+05	1.62E-05	2.52E-11
9	Human IgG1	D2E7	0.47 - 1.45	3.44E+05	6.84E-05	1.99E-10

[a]1 : 1 Langmuir model did not fit the experimental data very well.

[b]The shape of the experimental dissociation phase suggests that there might be more than one process involved.

[c]Analyte response level was very low.

Reactivity pattern matrix showing the binding ability of pairs of Mabs to rhTNFα

Pair-wise epitope mapping by Biacore

Sample	2° Soluble Immune complex (Ab:Ag ratio = 4:1)	1° Captured rhTNFα antagonist, 25 µg/ml		
		Remicade	D2E7	Segard
1	rhTNFα	+	+	+
2	rhTNFα + Mouse IgG	+	+	+
3	rhTNFα + Human IgG	+	+	+
4	rhTNFα + Peptech Mab 1	+	-	+
5	rhTNFα + Peptech Mab 25	+	+	+
6	rhTNFα + Peptech Mab 37	+	?	+
7	rhTNFα + Peptech Mab 42	-	?	+
8	rhTNFα + Peptech Mab 53	-	+	+
9	rhTNFα + Peptech Mab 54	+	-	-
10	rhTNFα + Remicade	-	-	-
11	rhTNFα + Segard	-	-	-
12	rhTNFα + D2E7	-	-	-

+ Pairs of Mabs that bind concurrently

- Pairs of Mabs that interfere in binding

ABBOTT-HUM 0145659
CONFIDENTIAL

Individual Biacore Kinetic Rate Parameters

Sample	Ab Class	Captured antibody	Stoich. range	On-rate (M-1s-1)	Off-rate (s-1)
1	Murine IgG	Peptech 001	0.23 - 0.47	1.04E+06	5.02E-04
2	Murine IgG	Peptech 25	0.31 - 0.64	8.31E+05	1.85E-04
3	Murine IgG	Peptech 37	- 0.03 - 0.09[c]	4.25E+05	1.47E-03
4	Murine IgG	[ab]Peptech 42	- 0.01 - 0.46	3.73E+04	3.85E-04
5	Murine IgG	[ab]Peptech 53	- 0.04 - 0.60	4.08E+04	4.08E-04
6	Murine IgG	Peptech 54	0.27 - 0.52	6.61E+05	3.37E-04
7	Human IgG1	Remicade	0.45 - 0.81	6.26E+05	3.56E-05
8	Murine IgG3	Segard	0.55 - 0.91	6.44E+05	1.62E-05
9	Human IgG1	D2E7	0.47 - 1.45	3.44E+05	6.84E-05
10	Human IgG1	[d]D2E7		4.82E+05	3.08E-05

[a]1 : 1 Langmuir model did not fit the experimental data very well.

[b]The shape of the experimental dissociation phase suggests that there might be more than one process involved.

[c]Analyte response level was very low.

[d]AFP04C D2E7 Reference standard tested May.15.2002

ABBOTT-HUM 0145660
CONFIDENTIAL

K_D (M)
4.83E-10
2.23E-10
3.45E-09
1.03E-08
9.99E-09
5.10E-10
5.69E-11
2.52E-11
1.99E-10
6.39E-11

ABBOTT-HUM 0145661
CONFIDENTIAL

Pair-wise epitope mapping by Biacore using captured Segard

Sample	2° Soluble Immune complex (Ab:Ag ratio = 4:1)	1° Captured rhTNFα antagonist, 25 µg/ml		
		Segard (RU's)	Binding	Do antibodies share a similar binding epitope?
1	rhTNFα	1176	+	Not applicable
2	rhTNFα + Mouse IgG	1010	+	Not applicable
3	rhTNFα + Human IgG	922	+	Not applicable
4	rhTNFα + Peptech Mab 1	1005	+	No
5	rhTNFα + Peptech Mab 25	637	+	No
6	rhTNFα + Peptech Mab 37	1052	+	No
7	rhTNFα + Peptech Mab 42	458	+	No
8	rhTNFα + Peptech Mab 53	411	+	No
9	rhTNFα + Peptech Mab 54	907	+	No
10	rhTNFα + Remicade	10	-	Yes
11	rhTNFα + Segard	106	-	Yes
12	rhTNFα + D2E7	- 26	-	Yes

Sample	2° Soluble Antibody only	1° Captured rhTNFα antagonist, 25 µg/ml		
		Segard (RU's)	Binding	Comment
1	rhTNFα	1091	+	Stoichiometry = 0.90
2	Mouse IgG	- 3	-	Isotype matched control
3	Human IgG	- 13	-	Isotype matched control
4	Peptech Mab 1	1	-	
5	Peptech Mab 25	- 21	-	
6	Peptech Mab 37	5	-	
7	Peptech Mab 42	- 17	-	
8	Peptech Mab 53	- 19	-	
9	Peptech Mab 54	- 7	-	
10	Remicade	- 31	-	
11	Segard	131	-	Very little unwanted binding
12	D2E7	- 30	-	

ABBOTT-HUM 0145662
CONFIDENTIAL

Pair-wise epitope mapping by Biacore using captured D2E7

1° Captured rhTNFα antagonist, 25 µg/ml

Sample	2° Soluble Immune complex (Ab:Ag ratio = 4:1)	D2E7 (RU's)	Binding	Do antibodies share a similar binding epitope?
1	rhTNFα	1245	+	Not applicable
2	rhTNFα + Mouse IgG	929	+	Not applicable
3	rhTNFα + Human IgG	951	+	Not applicable
4	rhTNFα + Peptech Mab 1	1130	+	No
5	rhTNFα + Peptech Mab 25	- 40	-	Yes
6	rhTNFα + Peptech Mab 37	968	+	No
7	rhTNFα + Peptech Mab 42	216	?	Maybe overlapping epitopes
8	rhTNFα + Peptech Mab 53	189	?	Maybe overlapping epitopes
9	rhTNFα + Peptech Mab 54	541	+	No
10	rhTNFα + Remicade	80	-	Yes
11	rhTNFα + Segard	- 50	-	Yes
12	rhTNFα + D2E7	107	-	Yes

1° Captured rhTNFα antagonist, 25 µg/ml

Sample	2° Soluble Antibody only	D2E7 (RU's)	Binding	Comment
1	rhTNFα	1236	+	Stoichiometry = 0.90
2	Mouse IgG	- 50	-	Isotype matched control
3	Human IgG	76	-	Isotype matched control
4	Peptech Mab 1	- 53	-	
5	Peptech Mab 25	- 56	-	
6	Peptech Mab 37	- 53	-	
7	Peptech Mab 42	- 50	-	
8	Peptech Mab 53	- 46	-	
9	Peptech Mab 54	- 48	-	
10	Remicade	60	-	Very little unwanted binding
11	Segard	- 47	-	
12	D2E7	98	-	Very little unwanted binding

ABBOTT-HUM 0145663
CONFIDENTIAL

Pair-wise epitope mapping by Biacore using captured Remicade

Sample	2° Soluble Immune complex (Ab:Ag ratio = 4:1)	1° Captured rhTNFα antagonist, 25 µg/ml		
		Remicade (RU's)	Binding	Do antibodies share a similar binding epitope?
1	rhTNFα	1193	+	Not applicable
2	rhTNFα + Mouse IgG	868	+	Not applicable
3	rhTNFα + Human IgG	872	+	Not applicable
4	rhTNFα + Peptech Mab 1	1099	+	No
5	rhTNFα + Peptech Mab 25	614	+	No
6	rhTNFα + Peptech Mab 37	959	+	No
7	rhTNFα + Peptech Mab 42	45	-	Yes
8	rhTNFα + Peptech Mab 53	27	-	Yes
9	rhTNFα + Peptech Mab 54	788	+	No
10	rhTNFα + Remicade	113	-	Yes
11	rhTNFα + Segard	- 48	-	Yes
12	rhTNFα + D2E7	91	-	Yes

Sample	2° Soluble Antibody only	1° Captured rhTNFα antagonist, 25 µg/ml		
		Remicade (RU's)	Binding	Comment
1	rhTNFα	1268	+	Stoichiometry = 0.88
2	Mouse IgG	- 62	-	Isotype matched control
3	Human IgG	49	-	Isotype matched control
4	Peptech Mab 1	- 59	-	
5	Peptech Mab 25	- 53	-	
6	Peptech Mab 37	- 51	-	
7	Peptech Mab 42	- 51	-	
8	Peptech Mab 53	- 41	-	
9	Peptech Mab 54	- 51	-	
10	Remicade	106	-	Very little unwanted binding
11	Segard	- 43	-	
12	D2E7	78	-	Very little unwanted binding

ABBOTT-HUM 0145664
CONFIDENTIAL

Pair-wise epitope mapping by Biacore

Sample	2° Soluble Immune complex (Ab:Ag ratio = 4:1)	1° Captured rhTNFα antagonist, 25 µg/ml		
		Remicade	D2E7	Segard
1	rhTNFα	+	+	+
2	rhTNFα + Mouse IgG	+	+	+
3	rhTNFα + Human IgG	+	+	+
4	rhTNFα + Peptech Mab 1	+	+	+
5	rhTNFα + Peptech Mab 25	+	-	+
6	rhTNFα + Peptech Mab 37	+	+	+
7	rhTNFα + Peptech Mab 42	-	?	+
8	rhTNFα + Peptech Mab 53	-	?	+
9	rhTNFα + Peptech Mab 54	+	+	+
10	rhTNFα + Remicade	-	-	-
11	rhTNFα + Segard	-	-	-
12	rhTNFα + D2E7	-	-	-

ABBOTT-HUM 0145665
CONFIDENTIAL